Oncotarget

Reviews:

This article has been corrected. Correction in: Oncotarget. 2018; 9:32097.

Genetically enhanced T lymphocytes and the intensive care unit

Tiberiu Tat, Huming Li, Catalin-Sorin Constantinescu, Anca Onaciu, Sergiu Chira, Ciprian Osan, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Cristian Berce, Sebastian Tranca, Delia Dima, Ioana Berindan-Neagoe, Jianliang Shen, Ciprian Tomuleasa _ and Liren Qian

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:16557-16572. https://doi.org/10.18632/oncotarget.24637

Metrics: PDF 1271 views  |   HTML 1903 views  |   ?  


Abstract

Tiberiu Tat1,2, Huming Li3, Catalin-Sorin Constantinescu1,4, Anca Onaciu5, Sergiu Chira5, Ciprian Osan5, Sergiu Pasca5, Bobe Petrushev5, Vlad Moisoiu5, Wilhelm-Thomas Micu5, Cristian Berce6, Sebastian Tranca2, Delia Dima7, Ioana Berindan-Neagoe5, Jianliang Shen8, Ciprian Tomuleasa7,9 and Liren Qian8

1Intensive Care Unit, Ion Chiricuta Clinical Cancer Research, Cluj Napoca, Romania

2Department of Anesthesiology-Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

3Department of Pulmonary and Critical Care Medicine, Navy General Hospital of PLA, Beijing, China

4Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

5Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

6Department of Experimental Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

7Department of Hematology, Ion Chiricuta Clinical Cancer Research, Cluj Napoca, Romania

8Department of Hematology, Navy General Hospital of PLA, Beijing, China

9Research Center for Functional Genomics and Translational Medicine / Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

Correspondence to:

Ciprian Tomuleasa, email: ciprian.tomuleasa@umfcluj.ro

Keywords: hematological malignancies; chimeric antigen receptor-modified T cell; donor lymphocyte infusion; stem cell transplant; immunotherapy

Received: December 01, 2017     Accepted: February 26, 2018     Published: March 27, 2018

ABSTRACT

Chimeric antigen receptor-modified T cells (CAR-T cells) and donor lymphocyte infusion (DLI) are important protocols in lymphocyte engineering. CAR-T cells have emerged as a new modality for cancer immunotherapy due to their potential efficacy against hematological malignancies. These genetically modified receptors contain an antigen-binding moiety, a hinge region, a transmembrane domain, and an intracellular costimulatory domain resulting in lymphocyte T cell activation subsequent to antigen binding. In present-day medicine, four generations of CAR-T cells are described depending on the intracellular signaling domain number of T cell receptors. DLI represents a form of adoptive therapy used after hematopoietic stem cell transplant for its anti-tumor and anti-infectious properties. This article covers the current status of CAR-T cells and DLI research in the intensive care unit (ICU) patient, including the efficacy, toxicity, side effects and treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24637